Long-term follow-up and failure predictors of Botox 1 300 UI injections in the treatment of neurogenic detrusor overactivity (NDO) Method.-Retrospective (2002 -2011 monocentric study of patients with overactive bladder, treated with 300 IU Botox 1 and self-catheterized. The evaluation criteria were clinical, urodynamic and ultrasound. The time to occurrence of failures was estimated by the Kaplan Meir. Groups were compared by the log rank test and Cox model. Results.-One hundred and eighty-three patients were included (165 SCI, 18 multiple sclerosis (MS)). At 3 years, 152 patients continued injections of intravesical botulinum toxin (83%) and 138 patients after 5 years (75.4%). We differentiated the true failures (32 patients), from discontinuation of treatment for side effects, poor tolerance of injections or neurological outcome. In the group of MS, there was only one true failure, other patients discontinued treatment for other reasons, including the worsening of the disease. In the group of patients who failed treatment, we find significantly in univariate analysis: -leakages after first injection, at 3 years (p <0.0001) and at 5 years (p <0.0001); -presence of febrile urinary tract infection after 1st injection, at 3 years (p = 0.01); -existence of detrusor overactivity after first injection, at 3 years (p = 0.05); -poor compliance before first injection, at 5 years (p = 0.04); -maximum detrusor pressure after first injection, at 3 years (p = 0.005) and at 5 years (p = 0.0004). In multivariate analysis, the following were significantly predictive of failure: leakages after 1st injection a t 3 years (p = 0.01) and at 5 years (p = 0.0004), sex of patients at 5 years (p = 0,01). The rate of symptomatic urinary tract infections was significantly reduced after toxin injection (p < 0.0001). Conclusion.-This study, which is representative of daily practice in a neurourology center, confirmed the effectiveness and safety of injections of 300 IU of Botox
1
. Some factors seem predictive of failure of intra-detrusor botulinum toxin (i.e. leakage after first injection). Results.-We considered four women suffering from spinal cord injury (one) or multiple sclerosis (three), unable to achieve self-catheterization through urethra because of functionnal loss of upper limbs or adductors spasticity or increase of weight. The surgical technique was vesicostomy using the Mitrofanoff principle, without enterocystoplasty, because of bladder stability under médical treatment and comorbidities; the native bladder was fixed to the inner face of the abdominal wall. The mean operation time was 188 min. Minor complications (stoma stenosis and wound dehiscence) and quality of life were not different from patients who underwent enterocystoplasty. One patient had a Bricker three years after first surgery.
Conclusion.-Injection of botulinum toxine for overactive bladder seems to be an alternative to enterocystoplasty when realizing continent cystostomy in neurologic patients with comorbidities like multiple sclerosis. However, evolutivity of the pathology may lead to a second surgery due to inability to achieve catheterization through urethra or loss of efficiency of botulinum toxin. 
